California Department of Public Health





Karen L. Smith, MD, MPH Director and State Health Officer

Edmund G. Brown Jr Governor

Office of AIDS (OA)

Management Memorandum

AIDS Drug Assistance Program (ADAP)

Memorandum Number: 2017 – 05

DATE: June 26, 2017

TO: LOCAL ADAP COORDINATORS AND ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF ISENTRESS HD (NEW FORMULATION) TO THE ADAP FORMULARY

Effective July 1, 2017, raltegravir 1200 mg (Isentress HD) will be added to the ADAP formulary. This new formulation of Isentress, an integrase inhibitor, is to be taken once daily as two 600 mg tablets with or without food. The HD formulation received federal Food and Drug Administration (FDA) on May 30, 2017 for the treatment of individuals with HIV-1 infection, in combination with other antiretroviral drugs.

If you have any questions regarding the addition of this new drug formulation to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Sincerely,

Sandra Robinson, Chief

Jurden Lore

ADAP Branch

Office of AIDS

